Mostrando 10 resultados de: 12
Filtros aplicados
Subtipo de publicación
Article(12)
Publisher
Cancer Immunology, Immunotherapy(2)
Frontiers in Oncology(2)
Gerontology(2)
Immunity and Ageing(2)
Clinical and Translational Immunology(1)
Área temáticas
Enfermedades(10)
Farmacología y terapéutica(4)
Fisiología humana(3)
Microorganismos, hongos y algas(3)
Bioquímica(1)
Origen
scopus(12)
Association among Terminally Differentiated T Cells, Frailty, and Dependency in a Group of Cuban Centenarians
ArticleAbstract: Introduction: Centenarians are considered a model of successful aging. Cuba exhibits one of the oldePalabras claves:Centenarians, Frailty, Immunosenescence, inflammation, terminally differentiated T cellsAutores:Añe-Kouri A.L., Bicet Y.D.L.C., González A., Lage Davila A., Ledón N., Llanez-Gregorich E., Luaces P.L.o., Pereira K., Ramos M.B., Rodríguez M., Rodríguez Y., Saavedra Hernández D., Silva A., Suárez G.M., Tania Crombet, Vidal A.Fuentes:scopusAssociations among cytokines, EGF and lymphocyte subpopulations in patients diagnosed with advanced lung cancer
ArticleAbstract: Aging is considered the single most significant risk factor for the majority of common malignances iPalabras claves:B cells, Epidermal growth factor, Pro-inflammatory cytokines, T cells, terminally differentiated T cellsAutores:Añe-Kouri A.L., Catala M., Cordero L., García Verdecia B., González A., Lage Davila A., Ledón N., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Pereira K., Saavedra Hernández D., Salomón E.E., Sánchez M.G., Suárez G.M., Tania CrombetFuentes:scopusAugmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
ArticleAbstract: Background: CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shownPalabras claves:immune checkpoint inhibitor, immunotherapy, lung cancer, Non-small cell lung cancer, VaccineAutores:Attwood K., Cedeno C., Cinquino A., Dai T., Dozier A., Dy G.K., Ernstoff M., Evans R., Fisher D.T., Fountzilas C., Groman A., Hutson A., Johnson C., Lage Davila A., Lee K., Leon K., Luaces P.L.o., Mazorra Z., Mesa C., Muhitch J., Opyrchal M., Puzanov I., Reid M., Saavedra Hernández D., Santos-Morales O., Tania Crombet, Wallace P.K.Fuentes:scopusBiomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
ArticleAbstract: Purpose: There are well-known alterations occurring within the immune system with aging. CollectivelPalabras claves:cancer vaccine, Immunosenescence, Immunosenescence markers, Non-small cell lung cancerAutores:Fuentes K.P., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Neninger Vinageras E., Popa X., Saavedra Hernández D., Tania CrombetFuentes:scopusBiomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly
ArticleAbstract: The changes that occur in the immune system with aging are commonly termed immunosenescence. ImmunosPalabras claves:Biomodulina T, Immunosenescence, naïve T cells, Stem cell-like memory T cells, T cellsAutores:Aznar E., Fuertes S.A., García Verdecia B., González A., Lage Davila A., Luaces P.L.o., Mazorra Z., Saavedra Hernández D., Speiser D.E., Suárez G.M., Tania CrombetFuentes:scopusAn anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: Report of three cases
ArticleAbstract: In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the diPalabras claves:CD6 molecule, coronavirus 2, covid-19, cytokine-release syndrome, IL-6, Itolizumab, Monoclonal antibody, SARS-COV-2Autores:Añe-Kouri A.L., Berrio J., Caballero A., Caballero J.A., Cepeda M., Cervantes J.B., Figueredo C., Filgueira L.M., Herrera C., Leon K., Lorenzo G., Lovelle O.A., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania CrombetFuentes:scopusAn anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
ArticleAbstract: Background: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around thePalabras claves:covid-19, Cytokine release syndrome, IL-6, ItolizumabAutores:Añe-Kouri A.L., Betancourt J., Caballero A., Cepeda M., Chávez E., Filgueira L.M., Herrera C., Hidalgo C.J., Leon K., Lorenzo G., Manso L., Mazorra Z., Ramos M., Saavedra Hernández D., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopusImmune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody
ArticleAbstract: SARS-CoV-2 infection causes a range of clinical presentations and induces changes in both innate andPalabras claves:covid-19, eGFR, inflammation, nimotuzumab, SARS-COV-2, T cellsAutores:Añe-Kouri A.L., Armada J.J., González Y.Z., Gregorich E.M.L., Londres H.D., Luaces P.L.o., Martínez A.H., Medel L., Mena J., Ramos M., Saavedra Hernández D., Sánchez Y.H., Tania Crombet, Troche M.Fuentes:scopusImmunosenescence and gender: A study in healthy Cubans
ArticleAbstract: Background: The progressive decline in the immune function during ageing is termed immunosenescence.Palabras claves:Autores:de Jesús Badía Alvarez T., García Verdecia B., Lage Davila A., Leonard Rupalé I., Luaces P.L.o., Mazorra Z., Saavedra Hernández D., Tania CrombetFuentes:scopusTreatment of COVID-19 patients with the anti-CD6 antibody itolizumab
ArticleAbstract: Objectives: COVID-19 can lead to a hyperinflammatory state. CD6 is a glycoprotein expressed on maturPalabras claves:CD6, covid-19, Cytokine release syndrome, Itolizumab, Monoclonal antibody, SARS-COV2Autores:Arencibia M., Betancourt J., Caballero A., Cabrera L., Castillo U., Cepeda M., Despaigne R.E., Diaz H., Domecq M., Escalona A., Estevez D., Filgueira L.M., García Y., Hidalgo C.J., Leon K., Lorenzo G., Lorenzo P., Martinez A., Mazorra Z., Meriño E., Ortega L.M., Ramírez A., Ramos M., Saavedra Hernández D., Sánchez L., Sánchez N., Tania Crombet, Valenzuela-Silva C.M.Fuentes:scopus